As depression and anxiety are commonly observed in ALS patients (Stephens et al., 2016), the potential interaction between A2AR agonists and D2R agonists in the treatment of ALS patients requires caution and proper judgment. The gene discussed is DRD2; the disease is depressive symptom measurement.